InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (7 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
7
T+90 hit rate
0%
T+90 mean return
-32.5%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Eisner Mark, VP Exécutif. Director active across 2 companies, notably Vir Biotechnology, Inc.. In total, 25 reports have been recorded. Split: 0 buy · 7 sells. Total volume traded: €407k. History available since 4 October 2021. The latest transaction was disclosed on 24 February 2026 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Declarations25 total
1,616 shares@ US$9.532650.0% of flowCommon StockSEC:0001628280-26-012394
1,616 shares@ US$9.53260.0016% mcap50.0% of flowCommon StockSEC:0001628280-26-012394:0
40,000 shares0Common StockSEC:0001628280-25-007699:0
75,000 shares0Common StockSEC:0000950170-24-083951:0
1,860 shares@ US$0.96310.2% of flowCommon StockSEC:0001209191-23-048809:0
1,085 shares@ US$1.060.1% of flowCommon StockSEC:0001209191-23-048555:0
2,042 shares@ US$17.0383.7% of flowCommon StockSEC:0001209191-23-036054:0
1,090 shares@ US$18.832.2% of flowCommon StockSEC:0001209191-23-034288:0
9,182 shares@ US$18.783818.1% of flowCommon StockSEC:0001209191-23-023592:0
7,363 shares@ US$21.155917.0% of flowCommon StockSEC:0001209191-23-018063:0
1,187 shares@ US$21.872.8% of flowCommon StockSEC:0001209191-23-016362:0
32,500 shares0Common StockSEC:0001209191-23-012425:0
1,084 shares@ US$15.041.8% of flowCommon StockSEC:0001209191-22-059472:0
6,777 shares@ US$13.0110.3% of flowCommon StockSEC:0001209191-22-052381:0
756 shares@ US$13.091.1% of flowCommon StockSEC:0001209191-22-048555:0
1,141 shares@ US$9.612.8% of flowCommon StockSEC:0001209191-22-034041:0
6,442 shares@ US$12.0218.9% of flowCommon StockSEC:0001209191-22-022095:0
756 shares@ US$13.622.5% of flowCommon StockSEC:0001209191-22-015366:0
60,000 shares0Common StockSEC:0001209191-22-010452:0
7,043 shares@ US$14.8265.5% of flowCommon StockSEC:0001209191-22-001743
7,043 shares@ US$14.8224.8% of flowCommon StockSEC:0001209191-22-001743:0
4,338 shares@ US$12.6513.1% of flowCommon StockSEC:0001209191-21-067780:0
4,338 shares@ US$12.6534.5% of flowCommon StockSEC:0001209191-21-067780
74,520 shares0Common StockSEC:0001209191-21-059869
74,520 shares0Common StockSEC:0001209191-21-059869:0
25 of 25 declarations
About Eisner Mark
Mark Eisner is the Executive Vice President and Chief Medical Officer at Vir Biotechnology, Inc. and FibroGen Inc. He oversees the medical and research operations of the companies, ensuring innovation and compliance. Eisner plays a key role in developing medical treatments and improving patient outcomes.
